

# Devices Pipeline

## Medical Device Pathway: Aesthetics Device

Device/Brand Name	Potential Indication	Phase (Concept, Feasibility, Development, Confirmation)
CoolSculpting	Fat Reduction	████████████████
Volite	Fine Line Reduction	████████████████
Volux	Facial Volume	████████████████
Volbella	Tear Trough Reduction	████████████████
Revolve ENVI 600	Adipose Tissue Processing	████████████████
Voluma	Chin Augmentation	████████████████

## Medical Device Pathway: Eye Care Device

Device/Brand Name	Potential Indication	Phase (Concept, Feasibility, Development, Confirmation)
XEN	Angle Closure Glaucoma (45)	████████████████
XEN	Open Angle Glaucoma (63)	████████████████

As of May 20, 2020; does not include legacy Allergan programs designated for out-license or termination.

\*Partnered Asset Partnership Summary Below.  
AbbVie holds a license agreement to CoolSculpting from Mass General for (through AGN's purchase of Zeltiq)